Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan=" | ! colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | | colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin Examination | ||
|- | |- | ||
! colspan=" | ! colspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
Line 18: | Line 18: | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2 | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2 | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3 | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3 | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Risk factors | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Areas affected | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Areas affected | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features | ||
!Dermoscopy Features | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma''' | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* SCC in situ | * SCC in situ | ||
Line 36: | Line 37: | ||
* In fair-skinned individuals, SCCs most commonly arise in sites frequently exposed to the sun | * In fair-skinned individuals, SCCs most commonly arise in sites frequently exposed to the sun | ||
* In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring | * In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis | * Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis | ||
Line 46: | Line 48: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Lesions of invasive SCC are often asymptomatic but may be painful or pruritic. | | style="background: #F5F5F5; padding: 5px;" |Lesions of invasive SCC are often asymptomatic but may be painful or pruritic. | ||
| style="background: #F5F5F5; padding: 5px;" |Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor | | style="background: #F5F5F5; padding: 5px;" |Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor | ||
| style="background: #F5F5F5; padding: 5px;" |Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules | | style="background: #F5F5F5; padding: 5px;" |Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules | ||
| style="background: #F5F5F5; padding: 5px;" |Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions | | style="background: #F5F5F5; padding: 5px;" |Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions | ||
Line 53: | Line 55: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Keratoacanthoma''' | ||
| style="background: #F5F5F5; padding: 5px;" |keratocytic epithelial tumors | | style="background: #F5F5F5; padding: 5px;" |keratocytic epithelial tumors | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" |Initial lesion: small pink macule | |||
Later: papular quality and eventually forms a circumscribed nodule. | |||
| style="background: #F5F5F5; padding: 5px;" |The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias | |||
| style="background: #F5F5F5; padding: 5px;" |The center of the nodule typically demonstrates a prominent keratinous core. | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
* Skin color | |||
* Ultraviolet radiation | |||
* Genetics | |||
* Drug exposure (BRAF inhibitors) | |||
* Trauma (surgery, laser therapy, cryotherapy or accidental trauma) | |||
* Chemical carcinogens (tar, pitch, polyaromatic hydrocarbons) | |||
* Human papillomavirus infection | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
* Develops on sun-exposed areas of the skin.<ref name="pmid10949454">{{cite journal| author=Sánchez Yus E, Simón P, Requena L, Ambrojo P, de Eusebio E| title=Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant. | journal=Am J Dermatopathol | year= 2000 | volume= 22 | issue= 4 | pages= 305-10 | pmid=10949454 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10949454 }}</ref> | |||
* The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement<ref name="pmid205416762">{{cite journal| author=Ko CJ| title=Keratoacanthoma: facts and controversies. | journal=Clin Dermatol | year= 2010 | volume= 28 | issue= 3 | pages= 254-61 | pmid=20541676 | doi=10.1016/j.clindermatol.2009.06.010 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20541676 }}</ref> | |||
| style="background: #F5F5F5; padding: 5px;" |a history of rapid growth within weeks favors this diagnosis | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" |Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
* It is controversial whether keratoacanthomas represent a subtype of well-differentiated SCC or a separate entity | |||
* Dermoscopy may aid in clinically distinguishing KA from other lesions but cannot reliably distinguish KA from squamous cell carcinoma | |||
|- | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Muir-Torre | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome | ||
| style="background: #F5F5F5; padding: 5px;" | | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
| style="background: #F5F5F5; padding: 5px;" | | |||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Merkel cell carcinoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Merkel cell carcinoma''' | ||
Line 79: | Line 111: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | | style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | ||
Line 92: | Line 125: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth) | | style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth) | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 107: | Line 141: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 122: | Line 157: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 135: | Line 171: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* large, hyperchromatic, oval nuclei and little cytoplasm | * large, hyperchromatic, oval nuclei and little cytoplasm | ||
Line 150: | Line 187: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 163: | Line 201: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; | | style="background: #F5F5F5; padding: 5px;" |The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; | ||
Line 176: | Line 215: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 189: | Line 229: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Suspected due to evidence of eyelash loss | | style="background: #F5F5F5; padding: 5px;" |Suspected due to evidence of eyelash loss | ||
Line 202: | Line 243: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Develops in skeletal muscles usually | | style="background: #F5F5F5; padding: 5px;" |Develops in skeletal muscles usually | ||
Line 215: | Line 257: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 228: | Line 271: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 241: | Line 285: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease | | style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease | ||
| style="background: #F5F5F5; padding: 5px;" |chronic | | style="background: #F5F5F5; padding: 5px;" |chronic | ||
Line 254: | Line 299: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 267: | Line 313: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Caused by HPV | | style="background: #F5F5F5; padding: 5px;" |Caused by HPV | ||
Line 280: | Line 327: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 293: | Line 341: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 309: | Line 358: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Chronic condition | | style="background: #F5F5F5; padding: 5px;" |Chronic condition | ||
Line 322: | Line 372: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Chronic condition | | style="background: #F5F5F5; padding: 5px;" |Chronic condition | ||
Line 335: | Line 386: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 348: | Line 400: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 361: | Line 414: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 375: | Line 429: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 388: | Line 443: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Not contagious | | style="background: #F5F5F5; padding: 5px;" |Not contagious | ||
Line 401: | Line 457: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Chronic and sometimes accompanied by asthma | | style="background: #F5F5F5; padding: 5px;" |Chronic and sometimes accompanied by asthma | ||
Line 414: | Line 471: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 427: | Line 485: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 440: | Line 499: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 453: | Line 513: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue | | style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue | ||
| style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor | | style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor | ||
Line 467: | Line 528: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Rare autosomal-dominant disorder of the conjunctiva and oral mucosa | | style="background: #F5F5F5; padding: 5px;" |Rare autosomal-dominant disorder of the conjunctiva and oral mucosa | ||
Line 480: | Line 542: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 493: | Line 556: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements | | style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements | ||
| style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism | | style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism | ||
Line 507: | Line 571: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 520: | Line 585: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Typically | | style="background: #F5F5F5; padding: 5px;" |Typically | ||
Line 533: | Line 599: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 546: | Line 613: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 559: | Line 627: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Very rare | | style="background: #F5F5F5; padding: 5px;" |Very rare | ||
Line 572: | Line 641: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Keratosis follicularis | | style="background: #F5F5F5; padding: 5px;" |Keratosis follicularis | ||
Line 585: | Line 655: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Mycosis fungoides | | style="background: #F5F5F5; padding: 5px;" |Mycosis fungoides | ||
Line 598: | Line 669: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 613: | Line 685: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Verrucous carcinoma on the plantar foot | | style="background: #F5F5F5; padding: 5px;" |Verrucous carcinoma on the plantar foot | ||
Line 626: | Line 699: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |also known as giant condyloma acuminatum of Buschke-Loewenstein | | style="background: #F5F5F5; padding: 5px;" |also known as giant condyloma acuminatum of Buschke-Loewenstein | ||
|} | |} | ||
SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia. | SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia. | ||
<references /> | <references /> |
Revision as of 00:32, 18 February 2019
Diseases | Clinical manifestations | Para-clinical findings | Additional findings | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Skin Examination | |||||||||||
Lab Findings | Histopathology | |||||||||||
Names | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Risk factors | Areas affected | Unique features | Dermoscopy Features | |||
Cutaneous squamous cell carcinoma |
|
usually asymptomatic | well-demarcated, scaly patch or plaque | hyperkeratotic, or ulcerative lesions | Lesions are often erythematous but can also be skin colored or pigmented. | Any cutaneous surface, including the head, neck, trunk, extremities, oral mucosa, shoulders, chest and back |
|
|
SCC in situ lesions tend to grow slowly, enlarging over the course of years | |||
Invasive squamous cell carcinoma | Lesions of invasive SCC are often asymptomatic but may be painful or pruritic. | Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor | Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules | Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions | Poorly differentiated tumors may have ulceration, hemorrhage, or areas of necrosis. | |||||||
Keratoacanthoma | keratocytic epithelial tumors | Initial lesion: small pink macule
Later: papular quality and eventually forms a circumscribed nodule. |
The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias | The center of the nodule typically demonstrates a prominent keratinous core. |
|
a history of rapid growth within weeks favors this diagnosis | Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC |
| ||||
Muir-Torre | incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome | |||||||||||
Merkel cell carcinoma | Starts on areas of skin exposed to the sun | Single pink, red, or purple shiny bump | Painless | Blue-red, dome-shaped nodule | ||||||||
Nodular malignant melanoma | Lump that has been rapidly growing over the past weeks | Cells proliferate downwards through the skin (vertical growth) |
| |||||||||
Amelanotic melanoma | Color usually pink, purple or normal skin color | Usually have an asymmetrical shape with an irregular border | Red, nonspecific lesion with slightly elevated borders |
| ||||||||
Basal cell carcinoma | Coarse scale lesion | |||||||||||
Superficial basal cell carcinoma | Scaly patch | Erythematous lesion |
|
|||||||||
Nodular basal cell carcinoma | Pearly papule with telangiectasias | |||||||||||
Cutaneous metastases of internal malignancy | Other sites lungs, liver, brain, skin, or bone. | The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; | ||||||||||
Benign Skin Lesions | ||||||||||||
Sebaceous cell carcinoma | Yellow-nodule | Suspected due to evidence of eyelash loss | ||||||||||
Rhabdomyosarcoma | Bulging of the eye or a swollen eyelid | Develops in skeletal muscles usually | ||||||||||
Actinic keratoses | Pain | Hyperkeratosis | Erythema | less pigmentation, and tend to be somewhat smaller in size. | ||||||||
Prurigo nodules | Hard lesion | Itchy lumps | ||||||||||
Paget disease | Eczema-like rash of the skin | Around the genital regions of males and females. | Similar to mammary paget disease | chronic | ||||||||
Inflamed seborrheic keratosis | Waxy, "stuck on," often hyperkeratotic appearance | |||||||||||
Viral warts | Verrucous lesion | Caused by HPV | ||||||||||
Pyogenic granuloma | Rapidly growing | Red, dome-shaped | Friable papule with a collarette of scale | |||||||||
Bowenoid papulosis | multiple, red- to brown-colored, small papules that |
| ||||||||||
Nummular eczema | Itchy lesions | Coin shaped spots | Chronic condition | |||||||||
Psoriasis | Flaking, inflammation | Thick, white, silvery, or red patches of skin | Chronic condition | |||||||||
Pyoderma gangrenosum | Purulent ulcer | Ragged and violaceous border | ||||||||||
Venous stasis ulcers | ||||||||||||
Traumatic ulcers | ||||||||||||
Sebaceous Hyperplasia | Lesions can be single or multiple lesions |
Yellowish, soft, small papules on the face |
Usually on the nose, cheeks, and forehead | |||||||||
Allergic Contact Dermatitis | Itchy rash | Red rash | Not contagious | |||||||||
Atopic Dermatitis | Itchy rash | Fever | Red rash | Chronic and sometimes accompanied by asthma | ||||||||
Atypical Fibroxanthoma | Erythematous, dome-shaped papule | |||||||||||
Nevus | ||||||||||||
Chemical Burns | ||||||||||||
Limbal Dermoid | Contains choristomatous tissue | Benign congenital tumor | ||||||||||
Benign hereditary intraepithelial dyskeratosis | Rare autosomal-dominant disorder of the conjunctiva and oral mucosa | |||||||||||
primary acquired melanosis | ||||||||||||
Fibrous xanthoma | Containing fibromatous elements | Arises due to disturbed systemic lipid metabolism | ||||||||||
Inflamed seborrheic keratosis | Inflamed and hyperpigmented | On dermatoscopic evaluation, presence of horned cysts and hairpin-shaped blood vessels | ||||||||||
Juvenile xanthogranuloma | Reddened, yellowish-tan color of lesions | Slightly raised bumps | Typically | |||||||||
Cutaneous fungal infections | ||||||||||||
Desmoplastic trichoepithelioma | ||||||||||||
Adnexal carcinoma | Very rare | |||||||||||
Darier disease | Keratosis follicularis | |||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides | |||||||||||
Marjolin's ulcer | Lesions in sites of chronic wounds and scars | Excessive granulation tissue, | Rolled or everted wound margins | Bleeding on touch |
| |||||||
Epithelioma cuniculatum | Increased size | Verrucous carcinoma on the plantar foot | ||||||||||
Anogenital | also known as giant condyloma acuminatum of Buschke-Loewenstein |
SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia.
- ↑ Sánchez Yus E, Simón P, Requena L, Ambrojo P, de Eusebio E (2000). "Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant". Am J Dermatopathol. 22 (4): 305–10. PMID 10949454.
- ↑ Ko CJ (2010). "Keratoacanthoma: facts and controversies". Clin Dermatol. 28 (3): 254–61. doi:10.1016/j.clindermatol.2009.06.010. PMID 20541676.